PKM and metabolic disease: Together, these data suggested that TEPP-46 treatment in vivo may hold therapeutic promise in limiting severity of obesity-associated metabolic diseases and that the beneficial actions of TEPP-46 treatment in obese mice may in part depend on adipocyte PKM2 expression.